Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson's Disease and Movement Disorders®

Core Insights - ATH434 shows potential as a disease-modifying therapy for Multiple System Atrophy (MSA), with interim data indicating stabilization of clinical symptoms and biomarkers in clinical responders [1][2][3] Group 1: Clinical Trial Results - In the ATH434-202 Phase 2 open-label study, 30% of participants demonstrated stable or improved clinical outcomes, indicating a potential disease-modifying effect [2][3] - Clinical responders exhibited stability in objective biomarkers such as brain iron and neurofilament light chain (NfL) levels, suggesting that ATH434 may slow neurodegeneration [4][5] - The average increase in NfL levels for clinical responders was significantly lower compared to participants in the bioMUSE natural history study, indicating a favorable response to treatment [4] Group 2: Presentation Highlights - Data presented at the International Congress of Parkinson's Disease and Movement Disorders included findings from both Phase 2 clinical trials and preclinical studies, emphasizing the potential of ATH434 to modify disease progression [2][3] - The interim data from the ATH434-202 trial showed that while all participants experienced brain volume declines consistent with MSA progression, clinical responders maintained stable brain volumes at 12 months [3] - ATH434 was well tolerated, with no serious drug-related adverse events reported, highlighting its favorable safety profile [3] Group 3: Future Expectations - The company anticipates presenting topline data from the ATH434-201 trial in January 2025 and the 12-month data from ATH434-202 later in the year [2][10][11] - The ATH434-201 trial is a randomized, double-blind, placebo-controlled study focusing on early-stage MSA patients, while the ATH434-202 trial targets those with more advanced MSA [10][11] Group 4: Background on MSA and ATH434 - MSA is a rare neurodegenerative disease characterized by autonomic dysfunction and movement impairment, affecting at least 15,000 individuals in the U.S. with no approved therapies to slow disease progression [13] - ATH434 is designed to inhibit the aggregation of pathological proteins and restore normal iron balance in the brain, showing promise in treating both MSA and Parkinson's disease [8][9][16]